Time-in-Range variable is key to glycemic control in people with diabetes

Diabetes, whose prevalence in Spain has reached 14.8%, affects 1 in 7 people, being the second highest rate in Europe. It is a disease that, if not adequately controlled, can produce very serious associated complications such as cardiovascular disease, amputations or loss of vision, generating a high level of dependence and the need for patient care.

From this situation derives the importance of adherence to treatment, glucose control but also weight control, blood pressure, etc. These are undoubtedly the

pillars to prevent or mitigate the serious complications of this disease) and decision making by the patient (e.g., insulin dose adjusted to intake).

Read:  Boric sets salary caps and establishes a restriction on the hiring of relatives in La Moneda

One of the outstanding keys to move towards better diabetes control involves taking Time in Range, also known as TIR, as a glycemic control variable, which allows us to know how long the person with diabetes spends with controlled glucose.

One in 10 adults are currently living with diabetes (year 2021).

This is a recent variable arising from new continuous glucose monitoring or glucose ‘flash’ devices, which allow at least 14 days’ worth of levels to be measured, over a 24-hour range, with a minimum of 70% data.

Unlike glycosylated hemoglobin, time in range makes it possible to know 24/7 how long one is within glycemic control.

Read:  European markets reach highs on U.S. inflation data

It should also be noted that smart insulin pens (smartpens) are currently emerging as a great ally of people with diabetes, very useful for ensuring good therapeutic adherence, as they make it possible to make the appropriate adjustments and monitor the insulin doses administered.

The Best Online Bookmakers February 28 2024

BetMGM Casino